American Leishmania spp: formycin B treatment of cutaneous leishmaniasis in mice.
Using foot-pad infection of female C57BL/6, DBA/2J and NMRI-IVIC mice as an animal model for American cutaneous leishmaniasis (ACL), we evaluated the inhibitory effect of Formycin B (FoB) on the infection produced by 7 different Leishmania isolates. When treatment was initiated some days, or even some weeks, after infection a significant leishmanistatic effect was detected on mice infected with all Leishmania isolates, which reached 30-55 weeks for some isolates. The optimal dose schedule was 1.25 mg/kg body weight/day, injected intraperitoneally for 20 consecutive days. Significant differences in the sensitivity of various Leishmania spp. to FoB were found, either in vivo, or in vitro where a high [3H]FoB incorporation rate was found only for certain Leishmania isolates. The low toxicity of this drug and the sensitivity of the 7 Leishmania isolates tested suggest that FoB could be useful in the treatment of ACL.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D006224:Cricetinae; D005260:Female; D005573:Formycins / Q000627:therapeutic use*; D007891:Leishmania / Q000187:drug effects; D007892:Leishmania braziliensis / Q000187:drug effects; D007894:Leishmania mexicana / Q000187:drug effects; D007896:Leishmaniasis / Q000188:drug therapy*; D008647:Mesocricetus; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA
D000903:Antibiotics, Antineoplastic; D005573:Formycins; C034561:formycin B